Regeneron Pharmaceuticals Inc (REGN)

Total asset turnover

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Revenue (ttm) US$ in thousands 13,044,200 13,025,200 12,601,200 12,306,100 12,113,500 13,654,100 14,171,800 16,451,800 16,014,400 13,499,700 12,328,800 9,147,000 8,455,000 8,201,600 7,974,500 7,957,900 7,839,900 7,598,200 7,213,600 6,889,000
Total assets US$ in thousands 33,080,200 32,163,300 30,657,500 30,059,900 29,214,500 27,677,800 27,205,800 26,348,700 25,434,800 23,671,500 21,485,900 17,772,200 17,163,300 16,084,000 14,428,700 15,757,500 14,805,200 13,939,300 13,173,600 12,854,800
Total asset turnover 0.39 0.40 0.41 0.41 0.41 0.49 0.52 0.62 0.63 0.57 0.57 0.51 0.49 0.51 0.55 0.51 0.53 0.55 0.55 0.54

December 31, 2023 calculation

Total asset turnover = Revenue (ttm) ÷ Total assets
= $13,044,200K ÷ $33,080,200K
= 0.39

Regeneron Pharmaceuticals, Inc.'s total asset turnover has been gradually declining over the past few quarters, indicating a decrease in the efficiency of the company's asset utilization. The total asset turnover ratio measures a company's ability to generate sales from its assets, with a higher ratio typically indicating better efficiency.

In Q4 2023, the total asset turnover ratio was 0.40, which means that for every dollar of assets the company had, it generated $0.40 in sales. This ratio remained relatively stable compared to the previous three quarters, which all stood at 0.41. However, there was a notable drop from the previous year, where the ratio was 0.42 in Q4 2022.

Looking back further to Q3 and Q2 of 2022, the total asset turnover was higher at 0.50 and 0.52, respectively, indicating that Regeneron Pharmaceuticals was more efficient in generating sales from its assets during that period. The highest total asset turnover was recorded in Q1 2022 at 0.63, suggesting the company's assets were highly utilized to generate sales at that time.

Overall, the declining trend in total asset turnover for Regeneron Pharmaceuticals, Inc. from 2022 to 2023 may raise concerns about the company's asset efficiency and its ability to generate sufficient sales from its asset base. It would be important for the company to analyze the underlying reasons for this decline and consider strategies to improve its asset utilization in order to enhance overall performance and profitability.


Peer comparison

Dec 31, 2023


See also:

Regeneron Pharmaceuticals Inc Total Asset Turnover (Quarterly Data)